ImmunityBio, Inc. (IBRX) vs Protagonist Therapeutics, Inc. (PTGX)
ImmunityBio, Inc. and Protagonist Therapeutics, Inc. are both Biotechnology companies. ImmunityBio, Inc. and Protagonist Therapeutics, Inc. are of similar size ($9.2B and $8.9B). ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; Protagonist Therapeutics, Inc. trades at 117×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 34.8%. Protagonist Therapeutics, Inc. has the higher net margin (29.4% vs −598.6%) and the higher return on invested capital (61.8% vs 0.00%). Across the 17 metrics below, Protagonist Therapeutics, Inc. leads on 11 and ImmunityBio, Inc. on 6.
Valuation
Profitability
| Metric | IBRX | PTGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.34% | 100.00% | 65.16% |
| Operating margin | (151.88%) | 20.69% | 0.00% |
| Net margin | (598.56%) | 29.40% | 0.00% |
| Free cash flow margin | (173.76%) | 46.31% | 0.00% |
| Return on equity | 122.85% | 10.98% | (57.72%) |
| Return on assets | (192.58%) | 10.34% | (49.22%) |
| Return on invested capital | 0.00% | 61.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack